.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
US Army
US Department of Justice
Mallinckrodt
Baxter
Federal Trade Commission
Cipla
Argus Health
Cerilliant
Farmers Insurance

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,807,135

« Back to Dashboard

Which drugs does patent 7,807,135 protect, and when does it expire?


Patent 7,807,135 protects NEURACEQ and is included in one NDA.

This patent has twenty-nine patent family members in twenty-four countries.

Summary for Patent: 7,807,135

Title:Stilbene derivatives and their use for binding and imaging amyloid plaques
Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Inventor(s): Kung; Hank F. (Wynnewood, PA), Kung; Mei-Ping (Wynnewood, PA), Zhuang; Zhi-Ping (Lansdale, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:11/305,333
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Piramal Imaging
NEURACEQ
florbetaben f-18
SOLUTION;INTRAVENOUS204677-001Mar 19, 2014RXYesYes7,807,135► SubscribeYY NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,807,135

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,072Stilbene derivatives and their use for binding and imaging amyloid plaques► Subscribe
8,465,726Stilbene derivatives and their use for binding and imaging amyloid plaques► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,807,135

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine91996► Subscribe
Slovenia2213652► Subscribe
Singapore194363► Subscribe
Portugal2213652► Subscribe
New Zealand555942► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Baxter
Daiichi Sankyo
Cantor Fitzgerald
Argus Health
US Department of Justice
Federal Trade Commission
Farmers Insurance
Mallinckrodt
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot